Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-world use of lecanemab: patient pathway findings from a US multicenter study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Cognitive Trajectories After Hospitalization for COVID-19: A 36-Month Longitudinal Study.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same author

Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination.

Neurology·2026
Same author

The Cortico-Cortical and Subcortical Circuits of the Human Brain Language Centers Including the Dual Limbic and Language Functioning Fiber Tracts.

Brain sciences·2026
Same author

Attachment Insecurity and Well-Being in Dementia Spousal Caregivers: The Moderating Role of Marital Satisfaction.

Biopsychosocial science and medicine·2026
Same author

The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study.

The journal of prevention of Alzheimer's disease·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Madison Shyer1, Kristofer Harris2, Dulin Wang1

  • 1UTHealth Houston, Houston, TX, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

阿尔茨海默病 (AD) 试验中的快速进展者 (RP) 与缓慢进展者 (SP) 相比,显示出明显的临床和生物标志物差异. 了解这些变异对于优化临床试验设计和AD治疗策略至关重要.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 临床试验 临床试验
  • 生物标志物 生物标志物

背景情况:

  • 阿尔茨海默病 (AD) 临床试验显示患者进展异质,将个人分为缓慢进展者 (SP) 和快速进展者 (RP).
  • 了解RP和SP的独特特征对于解释临床试验结果,评估药物疗效和告知护理策略至关重要.

研究的目的:

  • 研究阿尔茨海默病 (AD) 的快速进展者 (RP) 和缓慢进展者 (SP) 之间的临床,生化和成像差异.
  • 确定影响AD进展模式的因素及其对临床试验设计的影响.

主要方法:

  • 利用EXPEDITION 1随机对照试验中安慰剂组的非识别数据来定义RP (MMSE下降>10分) 和SP (从查到第80周没有MMSE下降).
  • 评估了人口统计学,迷你精神状态检查 (MMSE),血,脑脊液 (CSF),MRI和PET扫描变量,以确定RP和SP之间的统计学上显著差异.

主要成果:

  • 包括142名患者:33名RP (23.2%) 和109名SP (76.7%).
  • 在BMI,使用乙胆酶抑制剂和记忆剂,基线MMSE,基线血氨基酸β42,基线氨基酸PETSUVr,基线全脑体积和第80周全脑缩方面观察到显著差异.
  • 与SPs相比,RPs在80周显示出更大的MMSE下降 (-15.2),更高的CSF pTAU (12.7),降低海马体积 (-72) 和增加整脑缩 (14.8) 在80周.

结论:

  • 这项研究强调了阿尔茨海默病中RP和SP之间显著的临床,成像和生化差异.
  • 这些发现强调了临床试验中个性化方法的必要性,以适应不同的AD进展率.